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doi:10.1016/j.ejvs.2009.09.025Abstract This study aims to evaluate the value of VEGF as a surrogate marker for peripheral
vascular disease (PVD). Prior to treatment, serum VEGF levels were evaluated by enzyme-
linked immunosorbent assay (ELISA) in 293 PVD patients. Risk factors and clinical parameters
of PVD were documented. Twenty-six age-matched healthy volunteers served as controls.
Serum VEGF values strongly correlated with Fontaine stages (p< 0.006, stage IV vs. controls).
High VEGF values prior to treatment were associated with poor outcome. Serum VEGF
appears to indicate the severity of PVD and might serve as a surrogate indicator of disease
severity.
ª 2009 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Introduction
Vascular endothelial growth factor (VEGF) is expressed
under hypoxic conditions and leads to angiogenesis and
arteriogenesis. Matsui et al.1 showed in a smaller series that
serum VEGF values in PVD patients were elevated. Here, we
examined serum VEGF levels prospectively in a large1 369 2221; fax: þ49 941 369
@barmherzige-regensburg.de
ty for Vascular Surgery. Publishenumber of PVD patients and determined whether VEGF
might serve as a surrogate marker of PVD.
Report
Study design and patients
The study included 293 patients with a history of peripheral
vascular disease (PVD), who visited the ‘Vascular Center’,
University of Regensburg, between August 2004 and July
2005 receiving 350 treatments (e.g., surgery, intervention,
PGE1 and exercise). The study population consisted of 187
men and 106 women with a median age of 67.8 yearsd by Elsevier Ltd. All rights reserved.
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Figure 1 Serum VEGF levels in PVD patients with different
Fontaine stages prior to treatment. Results are shown as
median, 10th, 25th, 75th and 90th percentiles. *pZ 0.006
Fontaine stage IV versus control (Kruskal-Wallis ANOVA on
Ranks followed by Dunns method, Sigma Stat 2.03, Jandel
Scientific).
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197 patients received medication due to lipid disorders).
None of the patients had known cancer.
Twenty-six age-matched healthy volunteers (long-term
follow-up patients after minor hand surgery) served as
controls, including five smokers. All patients gave written
informed consent to participate in this study as approved
by the local ethics committee.
All patients received a physical examination, ankle to
brachial index, a standardised treadmill test and either
a magnetic resonance (MR) angiography or an angiogram.
Venous fasting blood samples of non-traumatic veni-
punctures were obtained. If traumatic punctures occurred,
an indwelling intravenous catheter was inserted and blood
was drawn 6 h later. Full blood count, low-density lipid
(LDL) and high-density lipid (HDL) cholesterol, triglyceride,
creatinine, VEGF and other analytes were determined. In
a subset of 10 patients, measurements were also performed
from the contralateral cubital vein and 24 h after the first
measurement.
Measurement of serum VEGF
Serum VEGF determination was performed because acti-
vated platelets are a major source of VEGF.2 Blood was
collected in plain vacutainer tubes with no additives.2
Samples were processed at room temperature 30e60 min
after collection centrifuged and serum stored at 80 C.
VEGF concentrations were determined using an enzyme-
linked immunosorbent assay (ELISA; Quantikine human
VEGF Immunoassay, R&D Systems). VEGF concentrations
(pg ml-1) were determined by constructing a standard curve
using recombinant VEGF.
Results
Correlation of baseline VEGF values and Fontaine
stages (Fig. 1)
Baseline VEGF values showed strong correlation with the
Fontaine stage in PVD patients. VEGF values in Fontaine IV
patients were almost doubled than in healthy controls.
Baseline VEGF values of the 12 patients who required
a major amputation were significantly higher than in
PVD patients without amputation (580 17 pg ml1 vs.
1216 125 pg ml1).
Influence of risk factors or co-morbidities
Smoking significantly increased VEGF levels in healthy
volunteers. However, regression analysis revealed that only
hypercholesterolaemia showed a significant inverse corre-
lation to VEGF levels (p< 0.032). Diabetes, hypertension or
smoking showed no correlation to VEGF values in PVD
patients (pZ 0.339, pZ 0.861, pZ 0.295, respectively).
Discussion
VEGF is an angiogenic factor that plays an important role in
the development of arteriosclerosis3 and is induced inischaemic tissue via HIF1a. Although exogenous application
of VEGF based on the concept of ‘therapeutic angiogenesis’
has already been performed in cardiovascular disease and
PVD, little is known about VEGF expression at different
stages of PVD. We aimed to close this gap by examining
whether VEGF might serve as a surrogate or prognostic
marker of PVD.
Our study presenting serum VEGF levels in 293 patients
confirms the observation of smaller series that serum VEGF
levels are elevated in PVD.1 Furthermore, we showed
a correlation of serum VEGF with the clinical Fontaine
stages (Fig. 1). This finding contrasts to a report from Porcu
et al.4 in smaller series of 36 patients, which showed no
VEGF increase with Fontaine classes.
Although there are several ways to evaluate PVD
severity, it is sometimes difficult to differentiate in
patients with diabetes between Fontaine stage III PVD and
other diseases such as neuropathy or spinal canal stenosis.
In such situations, serum VEGF might serve as a new
surrogate marker. New parameters are needed to deter-
mine PVD severity in a growing number of older patients
and those with multiple co-morbidities. We hypothesise
that VEGF might be such a parameter and further studies
with VEGF in combination with other parameters are
warranted.
We observed no correlation between VEGF values and
confounding risk factors of PVD including smoking, hyper-
tension and diabetes. This contrasts with the other reports3
showing higher VEGF levels in these patients. However, as
the Fontaine stages of these patients were not clearly
stated, the elevated VEGF values might also reflect greater
PVD severity. However, we noticed in accordance with
Kimura et al.,3 a significant inverse correlation between
hypercholesterolaemia and VEGF. Unfortunately, the
underlying effects of these observations cannot be deter-
mined from our study since we did not examine healthy
controls with these risk factors.
In summary, serum VEGF is a parameter that can be
determined easily and reliably in PVD. Serum VEGF values
332 A. Stehr et al.show a strong correlation with the clinical Fontaine stages
describing the severity of PVD and may serve as a surrogate
indicator of disease severity.
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